Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

A Study of PARG Inhibitor IDE161 in Participants with Advanced Solid Tumors ( IDE161-001)

Principal Investigator: Fountzilas, Christos

IDE196 (DAROVASERTIB) IN COMBINATION WITH CRIZOTINIB VERSUS INVESTIGATOR'S CHOICE OF TREATMENT AS FIRST-LINE THERAPY IN HLA-A2 NEGATIVE METASTATIC UVEAL MELANOMA (DAR-UM-2)

Principal Investigator: Switzer, Benjamin J

(ID-COMET) A Randomized Phase III Trial of Immediate Versus Six-Month Delayed Comprehensive Treatment of 1-10 Oligometastatic Tumors With or Without Synchronous Primary

Principal Investigator: Singh, Anurag K

NRG-HN009: RANDOMIZED PHASE II/III TRIAL OF RADIATION WITH
CISPLATIN AT 100 MG/M2 EVERY THREE WEEKS VERSUS RADIATION WITH WEEKLY CISPLATIN AT 40 MG/M2 FOR PATIENTS WITH LOCOREGIONALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)

Principal Investigator: Singh, Anurag K

Intensive Symptom Surveillance Guided by Machine Learning-Directed Risk Stratification (INSIGHT)

Principal Investigator: Singh, Anurag K

A Phase 2 Randomized Study with a non-Randomized Cohort: Assessing Single-fraction SBRT versus STandard PalliativE Radiation In Patients with Metastatic Disease (ASTEROID)

Principal Investigator: Singh, Anurag K